HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.

Abstract
Hepatic cystogenesis in polycystic liver disease (PLD) is associated with abnormalities in multiple cellular processes, including elevated cAMP and overexpression of histone deacetylase 6 (HDAC6). Disease progression in polycystic kidney (PCK) rats (an animal model of PLD) is attenuated by inhibition of either cAMP production or HDAC6. Therefore, we hypothesized that concurrent targeting of HDAC6 and cAMP would synergistically reduce cyst growth. Changes in hepatorenal cystogenesis were examined in PCK rats treated with a pan-HDAC inhibitor, panobinostat; three specific HDAC6 inhibitors, ACY-1215, ACY-738, and ACY-241; and a combination of ACY-1215 and the somatostatin receptor analogue, pasireotide. We also assessed effects of ACY-1215 and pasireotide alone and in combination on cell proliferation, cAMP production, and expression of acetylated α-tubulin in vitro in cultured cholangiocytes and the length of primary cilia and the frequency of ciliated cholangiocytes in vivo in PCK rats. Panobinostat and all three HDAC6 inhibitors decreased hepatorenal cystogenesis in PCK rats. ACY-1215 was more effective than other HDAC inhibitors and was chosen for combinational treatment. ACY-1215 + pasireotide combination synergistically reduced cyst growth and increased length of primary cilia in PCK rats. In cultured cystic cholangiocytes, ACY-1215 + pasireotide combination concurrently decreased cell proliferation and inhibited cAMP levels. These data suggest that the combination of drugs that inhibit HDAC6 and cAMP may be an effective therapy for PLD.
AuthorsMaria Lorenzo Pisarello, Tatyana V Masyuk, Sergio A Gradilone, Anatoliy I Masyuk, Jingyi F Ding, Pui-Yuen Lee, Nicholas F LaRusso
JournalThe American journal of pathology (Am J Pathol) Vol. 188 Issue 4 Pg. 981-994 (04 2018) ISSN: 1525-2191 [Electronic] United States
PMID29366679 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Pyrimidines
  • Receptors, Somatostatin
  • Tubulin
  • Somatostatin
  • Panobinostat
  • pasireotide
  • Cyclic AMP
  • Histone Deacetylase 6
  • ricolinostat
Topics
  • Acetylation
  • Animals
  • Bile Ducts (drug effects, metabolism, pathology)
  • Cell Proliferation (drug effects)
  • Cilia (metabolism)
  • Cyclic AMP (metabolism)
  • Cysts (drug therapy, pathology)
  • Disease Models, Animal
  • Drug Synergism
  • Female
  • Histone Deacetylase 6 (antagonists & inhibitors, metabolism)
  • Histone Deacetylase Inhibitors (pharmacology, therapeutic use)
  • Hydroxamic Acids (pharmacology, therapeutic use)
  • Liver Diseases (drug therapy, pathology)
  • Male
  • Panobinostat (pharmacology, therapeutic use)
  • Pyrimidines (pharmacology, therapeutic use)
  • Rats
  • Receptors, Somatostatin (agonists)
  • Somatostatin (analogs & derivatives, pharmacology, therapeutic use)
  • Tubulin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: